Comparative efficacy of nilotinib and dasatinib in newly diagnosed chronic myeloid leukemia: A matching-adjusted indirect comparison of randomized trials

Current Medical Research and Opinion

Volumn 27, Issue 6, 2011, Pages 1263-1271

  Signorovitch, James E ^a   Wu, Eric Q ^a   Betts, Keith A ^a   Parikh, Kejal ^a   Kantor, Evan ^a   Guo, Amy ^b   Bollu, Vamsi K ^b   Williams, Denise ^b   Wei, L J ^c   Deangelo, Daniel J ^d  

^a ANALYSIS GROUP   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

^c HARVARD UNIVERSITY   (United States)

^d DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

CML; Dasatinib; Efficacy; Matchingadjusted indirect comparison; Nilotinib

Indexed keywords

DASATINIB; IMATINIB; NILOTINIB;

ADULT; AGED; ANEMIA; ARTICLE; CHRONIC DISEASE; CHRONIC MYELOID LEUKEMIA; COMPARATIVE STUDY; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; FEMALE; FLUID RETENTION; HEADACHE; HEMATOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; MUSCULOSKELETAL PAIN; MYALGIA; NAUSEA; NAUSEA AND VOMITING; NEUTROPENIA; OVERALL SURVIVAL; PLEURA EFFUSION; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; SIDE EFFECT; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TREATMENT OUTCOME;

AGED; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; PROTEIN-TYROSINE KINASES; PYRIMIDINES; THIAZOLES; TREATMENT OUTCOME;

EID: 79956134848     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2011.576238     Document Type: Article

References (18)

1. Baccarani M, Cortes J, Pane F, et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol 2009;27:6041-51
2. Hughes TP, KaedaJ, BranfordS, et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med 2003;349:1423-32 (Pubitemid 37211057)
3. O'Brien SG, Guilhot F, Larson PA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003;348:994-1004 (Pubitemid 36302244)
4. DrukerBJ, Guilhot F, O'Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006;355:2408-17 (Pubitemid 44903745)
5. Cortes JE, Baccarani M, Guilhot F, et al. Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimization and selectivity study. J Clin Oncol 2010;28:424-30
6. Wei G, Rafiyath S, Liu D. First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib. J Hematol Oncol 2010;3:47
7. Saglio G, Kim DW, Issaragrisil S, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 2010;362:2251-9
8. Kantarjian H, Shah NP, Hochhaus A, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2010: 362:2260-70
9. Weisberg E, Manley PW, Cowan-Jacob SW, et al. Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia. Nat Rev Cancer 2007;7:345-56 (Pubitemid 46652483)
10. Hartmann JT, Haap M, Kopp HG, et al. Tyrosine kinase inhibitors-a review on pharmacology, metabolism and side effects. Curr Drug Metab2009;10:470-81
11. Steinberg M. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia. Clin Ther 2007;29:2289-308
12. Bucher HC, Guyatt GH, Griffith LE, et al. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol 1997;50:683-91 (Pubitemid 27341818)
13. Glenny AM, Altman DG, Song F, et al. Indirect comparisons of competing interventions. Health Technol Assess 2005;9:1-134,iii-iv
14. Signorovitch JE, Wu EQ, Yu AP, et al. Comparative effectiveness without head-to-head trials: a method for matching-adjusted indirect comparisons applied to psoriasis treatment with adalimumab or etanercept. Pharmacoeconomics 2010;28:935-45
15. Kantarjian H, Shah NP, Hochhaus A, et al. Dasatinib compared to imatinib in patients with newly diagnosed chronic-phase chronic myelogenous leukemia in chronic phase (CML-CP): twelve-month efficacy and safety from the phase III DASISION study. Presented at 2010 ASCO Annual Meeting, Abstract #LBA 6500
16. Lacobucci I, Saglio G, Rosti G, et al. Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patients. Clin Cancer Res 2006; 12: 3037-42. (Pubitemid 43837348)
17. Cortes J, Talpaz M, O'Brien S, et al. Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate. Clin Cancer Res 2005;11:3425-32 (Pubitemid 40627896)
18. Reed SD, Anstrom KJ, Li Y, et al. Updated estimates of survival and cost effectiveness for imatinib versus interferon-alpha plus low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukaemia. Pharmacoeconomics 2008;26:435-46 (Pubitemid 351572054)